CN102018768B - Traditional Chinese medicine used for curing migraine - Google Patents
Traditional Chinese medicine used for curing migraine Download PDFInfo
- Publication number
- CN102018768B CN102018768B CN201010604809A CN201010604809A CN102018768B CN 102018768 B CN102018768 B CN 102018768B CN 201010604809 A CN201010604809 A CN 201010604809A CN 201010604809 A CN201010604809 A CN 201010604809A CN 102018768 B CN102018768 B CN 102018768B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- group
- traditional chinese
- medicine
- migraine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a traditional Chinese medicine used for curing migraine which belongs to the medical preparation prepared from plant materials, in particular to a traditional Chinese medicinal preparation used for curing migraine. The invention discloses a medical preparation prepared from the following traditional Chinese medicines by weight percent: 30-70% of Ligusticum wallichii, 15-40% of mint, 10-30% of long pepper and 1-10% of borneol. The invention has the following advantages: the taste of medicine is light, the therapeutic effect is obvious, the side effect is little and the headache of a patient can be fast relieved after the patient takes the traditional Chinese medicine. The conventional preparation technology can be used, the traditional Chinese medicine is suitable for large-scale industrial production; and the traditional Chinese medicine has the advantages of available raw materials and the like.
Description
Technical field
The present invention relates to migrainous medicine of a kind of treatment and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Migraine starts from adolescence more or grows up in early days, is mainly between twenty and fifty period especially, to see 20～45 years old more.Developed country's average attack rate is 12%, and according to incompletely statistics, the migrainous prevalence of China adult reaches 7.7%～18.7%, and is ascendant trend year by year.The migraine frequency is indefinite, and wayward, and annual one to arriving every month one for several times to not waiting for several times sustainable 4～72 hours of headache outbreak, outbreak sustainable 2～3 weeks of persistent state.Severe headache during migraine, often with nauseating, vomiting, pale complexion heart rate, tachypnea, autonomic nerve symptoms such as gastrointestinal dysfunction have 85% women and 82% above male patient's ability to work forfeiture, are having a strong impact on patient's live and work.
In recent years, in, pathogenetic research all has remarkable progress to doctor trained in Western medicine to migraine.Pathogenetic research has following several theory to doctor trained in Western medicine to migraine: blood vessel theory (thinking relevant with the outer vasodilation of intracranial), neural blood vessel theory (thinking that the dysfunction with hypothalamus and limbic system has certain relation), neurotransmitter theory (think that increasing of 5-hydroxy tryptamine, prostacyclin can bring out migraine).Migrainous treatment is divided into the treatment of prophylactic treatment and stage of attack, different links that take place at migraine and factor adopts Drug therapy, non-drug therapy usually and the bonded method that changes lifestyles.Normal non-selective 5-hydroxytryptamine receptor agonist-Ergotamine preparation, selectivity 5-hydroxytryptamine receptor agonist-Qu Putan class, the anti-inflammatory analgesic-nonsteroidal anti-inflammatory drug etc. of adopting of doctor trained in Western medicine, take every day, the prevention outbreak, but side effect is big and be prone to drug dependence, when waiting to withdraw medicine, must gradually reduce dosage,, bring great inconvenience to the patient until stopping.
Chinese medicine is having its special advantages aspect the treatment migraine.Though the traditional Chinese medical science thinks that the migraine pathogenesis is complicated, is basis with the edema with the liver involved apraxia always, ailment said due to cold or exposure, blood stasis are mark.According to this theory, develop the migrainous Chinese patent medicine-TONGTIAN KOUFUYE of treatment, but blood circulation promoting and blood stasis dispelling, wind-expelling pain-stopping.Migraine due to being used for disturbing on stagnation of blood stasis, the ailment said due to cold or exposure, and oral Preparations such as treatment headache, dizzy compound cavel capsule, QUANTIANMA JIAONANG, the peaceful granule in sky, town, medicine containing gastrodia tuber for curing wind syndrome of head capsule, day relieving capsule.
Oral administration is the first-selected medication of present most of migraine treatment medicines, but because gastrointestinal tract to degraded and metabolism, liver first-pass effect and the blood brain barrier effect of medicine, causes the bioavailability of oral drugs to reduce.Nasal cavity and the cranial cavity uniqueness on anatomical physiology is got in touch and is made nasal-cavity administration is become possibility as the brain drug delivery approach, and the nasal-cavity administration approach is used for the attention that whole body therapeutic has caused research worker.Hussain in 1979 report Pu Naluoer rat is oral, the bioavailability after the intravenous injection, nasal mucosa administration, and the oral administration bioavailability is minimum, and the nasal mucosa administration is close with the intravenous injection bioavailability.The absorbing state of the Pu Naluoer that Hussain in 1980 etc. have compared different dosage form again rat and Canis familiaris L. after different way of administration, the bioavailability of nasal mucosa administration as a result is near 100%, and oral less than 20%.Prove that through animal experiment medicine can concentrate in brain behind the methotrexate nasal mist nasal-cavity administration, the dose in the cerebrospinal fluid is more than 10 times of intramuscular injection, can obviously improve the treatment that the leukemia brain soaks into.Nasal-cavity administration is as a kind of novel quick-acting administering mode, can reach quick-acting, purpose efficiently, is particularly useful for the emergency case sufferer.The nasal-cavity administration analgesic of development has apomorphine, fentanyl, benadryl, morphine, morphine Fructus Vitis viniferae hydrochlorate etc. at present, is chemicals, also is not at migraine.
Though the medicinal herb spray starting is late, development is very fast.In recent years, flourish along with the Chinese medicine cause, automiser spray, equipment are gradually improved, and it is ripe that preparation technology is tending towards, application is more extensive at aspects such as part, whole body, treatment of respiratory diseases and environment disinfecteds, has become an important branch in the field of traditional Chinese.But the nasal cavity administrated preparation that existing market is sold mainly is medicines such as treatment flu, rhinitis.Therefore, development is the migrainous nasal-cavity administration spray broad market prospect of treatment effectively, has significant social and economic benefit.
Summary of the invention
The objective of the invention is to develop the migrainous Chinese medicine of a kind of treatment, have flavour of a drug few, technology is simple, and therapeutical effect is obvious, and side effect is little, and this treats the medicament that the raw material of Chinese medicine that contains following percentage by weight in the migrainous medicine is made:
Rhizoma Chuanxiong 30～70%, Herba Menthae 15～40%, Fructus Piperis Longi 10～30%, Borneolum Syntheticum 1～10%
The above contains the medicament that the raw material of Chinese medicine of following percentage by weight is made:
Rhizoma Chuanxiong 40～60%, Herba Menthae 20～30%, Fructus Piperis Longi 15～25%, Borneolum Syntheticum 3～7%
The present invention contains the medicament that the best raw material of Chinese medicine of following percentage by weight is made:
Rhizoma Chuanxiong 50%, Herba Menthae 25%, Fructus Piperis Longi 20%, Borneolum Syntheticum 5%
The invention reside in described medicament is with Rhizoma Chuanxiong 30～70%, Herba Menthae 15～40%, and Fructus Piperis Longi 10～30%, Borneolum Syntheticum 1～10% adds conventional method of Chinese medicinal again and adds the adjuvant that pharmaceutically allows and make pharmaceutically useful dosage form: spray, liniment, patch.
This side's effect is warming the meridian and activating blood circulation, removing obstruction in the collateral to relieve pain.Indication: migraine, tension headache, card belongs to the liver-wind hemicrania.Headache, jumping pain or localized pain, nausea and vomiting, photophobia or fearness sound, dizziness, light red tongue, or purple dark or ecchymosis, petechia, thin fur, stringy pulse arranged.
The headache morbidity has substantial connection with liver, and " element is asked golden deficient the truth opinion " said: " spring-QI person, sick at head ".Liver is a viscus attriguted to wind and wood, and its gas lift is sent out, and reaches top, mountain peak and capable of face on its arteries and veins; Gas that outward should the spring life.So irritability is not normal, on violate women's head-ornaments and then have a headache.The prolonged illness headache, outbreak repeatedly, the venation block of then often holding concurrently, stagnation of QI and blood may bring about pain.The suitable dispelling wind collateral dredging of treatment, sharp key pain relieving.Rhizoma Chuanxiong is a monarch drug in the side, goes into liver, gallbladder meridian, and hot temperature rise is loose, blood-activating and qi-promoting, wind-expelling pain-stopping, is to treat headache product commonly used the most at all times, and the title of " kind first key medicine of having a headache of controlling " is arranged." the up head assigns the sea of blood ", promoting flow of QI and blood is walked to scurry meridians, is had to rise to have and fall, rise earlier and then fall, and can draw the gas rising of sun clearly, and " main apoplexy is gone into the brain headache." Zhang Xichun claims its " temperature is scurried mutually also, its power rises, descends, reaches, interior penetrating everywhere " outward.Zhu Danxi once emphasized to have a headache and must use Rhizoma Chuanxiong.Fructus Piperis Longi and Herba Menthae are ministerial drug altogether.Its acrid in the mouth of Fructus Piperis Longi, hot in nature in the side; Return warps such as stomach, large intestine, liver; The tool warming spleen and stomach for dispelling cold, the effect of therapeutic method to keep the adverse QI flowing downwards pain relieving." detailed outline " said: " Fructus Piperis Longi is headache, nasal sinusitis, toothache key medicine, gets it and hotly can go into Yangming Channel and loose superficial heat also." " book on Chinese herbal medicine is just read " then say: " flavor class Fructus Piperis goes into stomach and large intestine for Fructus Piperis Longi, the big heat of Da Xin, and positive bright medicine is also.Warming spleen and stomach for dispelling cold, the broken gas that stagnates, relieving stagnation, therapeutic method to keep the adverse QI flowing downwards expectorant, the superficial heat of the part of the body cavity above the diaphragm housing the heart and lungs that can loose again, diseases such as all toothache, wind syndrome of head, acid regurgitation belong to the bright wet fiery person of sun, all available this to control it." " book on Chinese herbal medicine justice " also cloud: " Fructus Piperis Longi, the principal agent of spleen-kidney vacuity cold.Only being on the point of the lake meaning is headache, nasal sinusitis key medicine, gets it and hotly can go into Yang Ming and loose superficial heat.By the intrinsic very cold disease of headache should be with the big temperature person of Da Xin, but nasal sinusitis, toothache, this all fiery disease, ancients' idol is covered the justice of also using corrigent with the hot medicine that looses ..." its acrid in the mouth of Herba Menthae, cool in nature.Return lung, Liver Channel.Soothing the liver, the clear sharp head of principal drug assistance Rhizoma Chuanxiong dispelling wind." Bencao Tujing " pointed out: Herba Menthae " main cold wind syndrome of the head ".The headache outbreak, head is pain relieving heavily.Borneolum Syntheticum is an adjuvant drug, and acrid in the mouth, hardship are cool in nature.GUIXIN, lung meridian.In order to the refreshment of having one's ideas straightened out, heat radiation pain relieving.Borneolum Syntheticum fragrance is walked to scurry, and the energy priming is up, through sick institute, and holding concurrently is the usefulness of messenger drug.All medicines share the effect of playing warming the meridian and activating blood circulation, removing obstruction in the collateral to relieve pain, suppressing the hyperactive liver to relieve the wind syndrome altogether.
Advantage of the present invention is that flavour of a drug are few, and technology is simple, and therapeutical effect is obvious, and side effect is little, and what the patient used can obtain the alleviation headache rapidly.
Specific embodiments:
Preparation method 1 of the present invention
A: the preparation method of Rhizoma Chuanxiong extract: getting Rhizoma Chuanxiong, pulverize, adopt percolation, is solvent with 70% ethanol, dipping is collected the medical material percolate, decompression recycling ethanol, medicinal liquid twice of ethyl acetate extraction (2 times, 1 times), combined ethyl acetate liquid, reclaim under reduced pressure gets Rhizoma Chuanxiong extract;
B: the preparation of Fructus Piperis Longi supercritical extract: get the Fructus Piperis Longi coarse powder, in the extractor of packing into, with supercritical extraction equipment (extracting pressure 27.5MPa, 50 ℃ of extraction temperature are resolved pressure 6MPa, 50 ℃ of resolution temperatures, add entrainer) extract, extract 2.5h, get Fructus Piperis Longi extract;
C: the preparation of Herba Menthae Haplocalycis volatile oil: get Herba Menthae, add 12 times of amounts of water, soaked 0.5 hour, adopt steam distillation to extract 2 hours, collect volatile oil and place standby;
A, b, c are merged mixing, add the recipe quantity Borneolum Syntheticum again and make dissolving fully, make in its mixed solvent that is dissolved in Polyethylene Glycol, ethanol, normal saline composition, make nasal mist.
Preparation method 2 of the present invention
A: the preparation method of Rhizoma Chuanxiong extract: getting Rhizoma Chuanxiong, pulverize, adopt percolation, is solvent with 70% ethanol, dipping is collected the medical material percolate, decompression recycling ethanol, medicinal liquid twice of ethyl acetate extraction (2 times, 1 times), combined ethyl acetate liquid, reclaim under reduced pressure gets Rhizoma Chuanxiong extract;
B: the preparation of Fructus Piperis Longi supercritical extract: get the Fructus Piperis Longi coarse powder, in the extractor of packing into, with supercritical extraction equipment (extracting pressure 27.5MPa, 50 ℃ of extraction temperature are resolved pressure 6MPa, 50 ℃ of resolution temperatures, add entrainer) extract, extract 2.5h, get Fructus Piperis Longi extract;
C: the preparation of Herba Menthae Haplocalycis volatile oil: get Herba Menthae, add 12 times of amounts of water, soaked 0.5 hour, adopt steam distillation to extract 2 hours, collect volatile oil and place standby;
Take by weighing various substrate and adjuvant by the prescription design, mix, heating in water bath makes molten, makes gel-type vehicle, and is standby; Other gets a, b, c and the Borneolum Syntheticum mixing of recipe quantity, with after an amount of dissolution with solvents with above-mentioned substrate mix homogeneously, the shop film is put and is dried to surface cure in the baking oven and the skeleton thin slice has favorable elasticity, cuts into the paster of prescribed level area, promptly gets paster.
Embodiment 1:
The present invention with percentage by weight (
W/
W)Calculate:
Rhizoma Chuanxiong 50%
Herba Menthae 25%
Fructus Piperis Longi 20%
Borneolum Syntheticum 5%.
Embodiment 2:
The present invention with percentage by weight (
W/
W)Calculate:
Rhizoma Chuanxiong 70%
Herba Menthae 15%
Fructus Piperis Longi 12%
Borneolum Syntheticum 3%.
Embodiment 3:
The present invention with percentage by weight (
W/
W)Calculate:
Rhizoma Chuanxiong 40%
Herba Menthae 40%
Fructus Piperis Longi 10%
Borneolum Syntheticum 10%.
Embodiment 4:
The present invention with percentage by weight (
W/
W)Calculate:
Rhizoma Chuanxiong 50%
Herba Menthae 19%
Fructus Piperis Longi 30%
Borneolum Syntheticum 1%.
: embodiment 6:
The present invention with percentage by weight (
W/
W)Calculate:
Rhizoma Chuanxiong 40%
Herba Menthae 35%
Fructus Piperis Longi 18%
Borneolum Syntheticum 7%.
Embodiment 7:
The migrainous Chinese medicine of a kind of treatment is with Rhizoma Chuanxiong 30～70%, Herba Menthae 15～40%, Fructus Piperis Longi 10～30%, Borneolum Syntheticum 1～10%
In addition conventional again method of Chinese medicinal is added the adjuvant that pharmaceutically allows and is made pharmaceutically useful dosage form: spray, liniment, patch.
Below prove the useful result of medicine provided by the present invention by the test of pesticide effectiveness.
Following experimental example and embodiment are used to further specify beneficial effect of the present invention, but are not limited to the present invention.
Shi Yan ﹝ 1 ﹞
60 rats are divided into the positive group of blank group, model control group, flunarizine, the basic, normal, high dosage group of the present invention at random.Blank group rat skin lower injection normal saline 1.0mL/kg; All the other group rat skin lower injection Nitro-Bid 9.5mg/kg set up experimental Nerve in Migraine Model, and the symptom that ears are rubescent, forelimb is frequently scratched one's head to occur, climb hints model animal head discomfort such as cage increased frequency is the index of modeling success.After the modeling success, model group is irritated stomach distilled water 1.0mL/kg; The flunarizine group is irritated stomach flunarizine 1.0mg/kg; The high, medium and low dosage group of the present invention is given and 0.2mL/kg, 0.1mL/kg, 0.05mL/kg collunarium respectively, number of times that (30min, 60min, 90min) forelimb is scratched one's head in symptom time of occurrence difficult to tackle and the unit interval section after the observation administration and appearance difficult to tackle and the time of alleviating, the gained result carries out the T check.The results are shown in Table 1, table 2.
The influence of table 1 pair nitroglycerin Migraine Rats number of times difficult to tackle (
± s, n=10)
Annotate: compare with model group,
★P＜0.05,
★ ★P＜0.01; Compare with positive group,
▲P＜0.05
The influence of the appearance difficult to tackle of table 2 pair nitroglycerin Migraine Rats, remission time (
± s, n=10)
Annotate: compare with model group,
★P＜0.05,
★ ★P＜0.01; Compare with positive group,
▲P＜0.05
The result of table 1 and table 2 shows, high, medium and low three the dosage groups of the present invention all can significantly reduce the rat migraine frequency difficult to tackle due to the nitroglycerin, compare with model group, significant difference (P＜0.05) is all arranged, wherein the effect with high dose group more obvious (P＜0.01).
Test (2) the present invention is to the influence of thermostimulation induced mice pain
Get 50 of female mices, body weight 18-22g, (select after hot plate last 5 second 30 seconds with interior and sufficient mice occurs licking, the failure eliminates) is divided into 5 groups at random, is respectively blank group, the positive group of flunarizine, the high, medium and low dosage group of the present invention, 10 every group.Behind the successive administration 7 days, be put on the hot plate to the time that pain reaction occurs, as the index of the threshold of pain certainly with stopwatch record mice during test.Measure the pain threshold of every mice earlier before administration, measure the pain threshold of mice behind administration 30 min respectively, as mice 60s is still reactionless mice is taken out, calculate with 60s its threshold of pain.The results are shown in Table 3.
The influence of table 3 pair thermostimulation induced mice pain (
± s)
Annotate: compare with the blank group,
★P＜0.05,
★ ★P＜0.01
Table 3 is the result show, three dosage of the present invention all can improve the mice pain threshold, with the blank group relatively, difference all has significance (P＜0.05), but and there was no significant difference between flunarizine (P〉0.05).
3) the present invention is to the influence of hemorheology of rat
Get 60 of rats, be divided into 6 groups at random, the positive group of blank group, model control group, aspirin, the high, medium and low dosage group of the present invention.Positive controls is irritated stomach aspirin 30mg/kg respectively every day, gives and 0.2mL/kg, 0.1mL/kg, 0.05mL/kg collunarium respectively for of the present invention group, and model group gives same concentrations normal saline collunarium, and blank group does not process.Every day 3 times, successive administration 7 days, 40min after the last administration, all laboratory animals are respectively by subcutaneous injection epinephrine 0.8mL/kg except that the blank group, and totally 2 times, two minor tick 4h, got blood in second day, and, measure and respectively organize the whole blood specific viscosity with 3.8% sodium citrate anticoagulant.The results are shown in Table 4.
Table 4 pair hemorheology of rat influence (
± SD, n=10)
Annotate: compare with the blank group,
▲P＜0.05,
▲ ▲P＜0.01; Compare with model group,
★P＜0.05
Table 4 is the result show, the present invention can reduce the whole blood viscosity of rat, compares with model group, and significant difference (P＜0.05) is arranged, and relatively do not have significant difference (P〉0.05) with the positive drug aspirin.
Test (4) the present invention is to the influence of clotting time of mice
Get 60 of female mices, body weight 18 ~ 22g is divided into 6 groups at random by body weight, the positive group of blank group, model control group, aspirin, the high, medium and low dosage group of the present invention.Except that blank group, all the other respectively organize every subcutaneous injection of reserpine of mice 0.7 mg/kg, totally 7 days, then one week of successive administration, after one week of administration, pluck eyeball and get blood, dripping 2 drops on the clean microscope slide, when blood flows out, pick up counting, gently choose blood with syringe needle behind the 30s, see to have or not the blood streak to occur, choose 1 time with pin every 15s later on, from timing begin to time that the blood streak occurs as clotting time.The results are shown in Table 5.
The influence of table 5 pair clotting time of mice (
± SD)
Annotate: compare with model group,
★P＜0.05,
★ ★P＜0.01
Table 5 is the result show, height of the present invention, middle dosage group all can shorten clotting time of mice, with the model group comparing difference significance (P＜0.05 or P＜0.01) arranged all.
5) acute toxicity test of the present invention
Choose 32 of healthy adult SD rats, body weight (200 scholar 20) g, male and female half and half are divided into blank group, group of solvents, of the present invention group, positive drug phinamide group, 8 every group at random.About 12 h of fasting before the test, the medicine group gives rat bilateral nasal cavity collunarium with the present invention with maximum administration volume 2.0ml/kg; Group of solvents, positive drug group give the equal volume contrast solution with method, and blank group is not done any processing.Conventional 7 d that raise after the administration, the response situation of the interior animal of 4 h after the observation administration writes down the response situation of animal between feeding period in detail, comprises the outward appearance of animal, behavioral activity, the mental status, two just and color, breath state, nose, eye, oral cavity have or not the abnormal secretion thing, body weight change, the zero-time of toxic reaction, the order of severity etc.
Result of the test shows that group of solvents, of the present invention group of rat active state all occurs and descend after the administration, lassitude, and close one's eyes, symptom such as the oral cavity tuberculosis of bone and joint; Reducing also appears in positive drug phinamide group activities in rats power, and each group all recovers normal successively behind the 5h.Blank group, group of solvents, of the present invention group, positive drug phinamide group 3h after administration successively begin feed.Respectively organize rat outward appearance sign in the 7d, behavioral activity is as usual, hair color gloss and respiratory frequency there is no unusually.Ingest, drinking-water, feces etc. is also no abnormal.Each is organized rat body weight and weight increase percentage rate thereof and learns check there was no significant difference (P〉0.05) by statistics, and it is dead that each organizes none example of rat.The result shows that nasal-cavity administration maximum dosage-feeding of the present invention is to rat acute toxicity less (seeing Table 6).
Respectively organize in table 6 acute toxicity test rat body weight situation of change (
± SD)
6) local irritation test of the present invention
32 of SD rat, male and female half and half, body weight (200 scholar 20) g after adaptability is raised 2 d, is divided into 4 groups by sex, body weight, 8 every group at random.The medicine group gives rat bilateral nasal cavity collunarium with the present invention with administration volume 0.1 μ l/kg, if the animal repellence is strong or drug leakage, can give several minutes intervals its disposition is relaxed, capable again administration after the nostril parts a little reaches more than the 4h to guarantee that medicinal liquid contacts with nasal cavity and respiratory mucosa; Group of solvents, positive drug group give the equal volume contrast solution with method; The normal control group is not done any processing.Administration every day 3 times, successive administration 7 d, the conventional raising.24 h after the last administration, dead 4 animals in every component other places, all the other each treated animals are observed 7 d (each group is put to death 2 animals) after 48 h to the drug withdrawal (each group is put to death 2 animals), the drug withdrawal respectively, investigate the variation of the local mucosa of animal overall health of patients, local excitation symptom and respiratory tract day by day by observation index.
Ordinary circumstance is observed: group of solvents, of the present invention group of rat all occur scratching nose, sneeze, get rid of first-class symptom after the administration, wherein the latter to scratch the nose phenomenon comparatively frequent; Nasal symptom also appears scratching in positive drug phinamide group.During the continuous 7 d nasal-cavity administrations, each organizes rat outward appearance sign, behavioral activity, breath state no abnormality seen, local excitation reaction such as do not see asthma, vomit, suffocate.Nasal cavity no abnormality seen secretions, the feces situation is no abnormal, and none example is dead.Each is organized rat body weight and weight increase percentage rate thereof and learns check there was no significant difference (P〉0.05) by statistics, the results are shown in Table 7.
Respectively organize in the table 7 local irritation test rat body weight situation of change (
± SD)
Histopathological examination: after the experiment respiratory mucosas such as the Mus nose of rat, larynx, trachea, bronchus are carried out the pathology cut sections for microscopic examination, each group there is no obvious impairment and changes and a large amount of cell infiltration, compare with normal group, there is not significant difference, show that thus compound recipe chrysanthemum ice nasal mist nasal cavity local application does not have obvious irritation, its clinical use is safer.Conclusion: the present invention does not have tangible local irritation to experimental animal.
Drug effect, toxicological study result show that the present invention is to having remarkable therapeutical effect by the NO type migraine due to the nitroglycerin; Can obviously improve the pain threshold of migraine mice, stimulation causes the mice pain reaction to hot plate the obvious suppression effect, shows that the present invention has significant analgesia role; Each dosage group of the present invention all can shorten clotting time of mice, with the model group comparing difference significance is arranged all, shows that it has the effect of antiplatelet aggregation; Can reduce the whole blood viscosity of rat to a certain extent, compare with model group, significant difference (P＜0.05) is arranged, prompting the present invention has the pharmacological effect of blood circulation promoting and blood stasis dispelling.
Dosage of the present invention is less to rat acute toxicity, and experimental animal is not had tangible local irritation.
Claims (4)
1. treat migrainous Chinese medicine for one kind, it is characterized in that the medicament of making by the Chinese medicine of following percentage by weight:
Rhizoma Chuanxiong 30～70%
Herba Menthae 15～40%
Fructus Piperis Longi 10～30%
Borneolum Syntheticum 1～10%.
2. according to the migrainous Chinese medicine of the described a kind of treatment of claim 1, the medicament of making by the Chinese medicine of following percentage by weight:
Rhizoma Chuanxiong 40～60%
Herba Menthae 20～30%
Fructus Piperis Longi 15～25%
Borneolum Syntheticum 3～7%.
3. according to the migrainous Chinese medicine of the described a kind of treatment of claim 1, the medicament of making by the Chinese medicine of following percentage by weight:
Rhizoma Chuanxiong 50%
Herba Menthae 25%
Fructus Piperis Longi 20%
Borneolum Syntheticum 5%.
4. according to the migrainous Chinese medicine of the described a kind of treatment of claim 1, it is characterized in that said medicament is with Rhizoma Chuanxiong 30～70%, Herba Menthae 15～40%, Fructus Piperis Longi 10～30%, Borneolum Syntheticum 1～10% adds conventional method of Chinese medicinal again and adds the adjuvant that pharmaceutically allows and make pharmaceutically useful dosage form: spray, liniment, patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010604809A CN102018768B (en) | 2010-12-24 | 2010-12-24 | Traditional Chinese medicine used for curing migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010604809A CN102018768B (en) | 2010-12-24 | 2010-12-24 | Traditional Chinese medicine used for curing migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018768A CN102018768A (en) | 2011-04-20 |
| CN102018768B true CN102018768B (en) | 2011-12-07 |
Family
ID=43860816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010604809A Expired - Fee Related CN102018768B (en) | 2010-12-24 | 2010-12-24 | Traditional Chinese medicine used for curing migraine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018768B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887753A (en) * | 2015-05-24 | 2015-09-09 | 太仓思瑞生物科技有限公司 | Use of external-application traditional Chinese medicine for treating migraine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347548A (en) * | 2008-06-16 | 2009-01-21 | 唐山康健生物科技有限公司 | Oral preparation for treating headache and preparation method |
| CN101612207A (en) * | 2009-07-16 | 2009-12-30 | 刘玉兰 | A kind of Chinese medicine for the treatment of headache and preparation method thereof |
| CN101829315A (en) * | 2010-07-01 | 2010-09-15 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating headache during menstruation and preparation method thereof |
-
2010
- 2010-12-24 CN CN201010604809A patent/CN102018768B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347548A (en) * | 2008-06-16 | 2009-01-21 | 唐山康健生物科技有限公司 | Oral preparation for treating headache and preparation method |
| CN101612207A (en) * | 2009-07-16 | 2009-12-30 | 刘玉兰 | A kind of Chinese medicine for the treatment of headache and preparation method thereof |
| CN101829315A (en) * | 2010-07-01 | 2010-09-15 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating headache during menstruation and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 于彪.川芎对药治疗头痛的临床应用.《中医药学报》.2001,(第02期), * |
| 侯嘉等.传统中药川芎的开发利用.《时珍国医国药》.2007,第18卷(第03期), * |
| 倪世秋等.利用信息分析法探讨偏头痛方药应用规律.《医学信息》.2006,第19卷(第02期), * |
| 孙启爱等.川芎荜拨散治疗血管神经性头痛28例.《中国乡村医药》.1998,(第03期), * |
| 李德华，赵淑红，孙焕全，申庆亮.颅痛灵口服液的药理研究.《中国中药杂志》.1994,第19卷(第05期), * |
| 郎宜男等.原发性三叉神经痛中医辨证治疗.《中医药信息》.1999,(第03期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018768A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103860941A (en) | Traditional Chinese medicine for treating schizophrenia and preparation method thereof | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN105769789A (en) | Clozapine tablets for treating schizophrenia and preparation method thereof | |
| CN108686009B (en) | Essential oil composition for preventing and/or treating rhinitis, preparation method, application and preparation | |
| CN102018768B (en) | Traditional Chinese medicine used for curing migraine | |
| CN104800236B (en) | Asarum total polysaccharide extractive and its extracting method and application with antitussive activity | |
| CN104840580A (en) | Traditional Chinese medicine for skin allergy nursing | |
| CN104435560B (en) | Alleviate the Chinese medicine composition and preparation method of incision pain after anesthesia disappears | |
| CN108653431B (en) | Pharmaceutical composition for preventing and treating rhinitis, preparation method, application and preparation thereof | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN106902317A (en) | It is a kind of to treat Chinese medicine composition of depression and preparation method thereof | |
| CN104189496A (en) | Traditional Chinese medicine preparation for treating neurasthenia and preparation method thereof | |
| CN105596480A (en) | Traditional Chinese medicine composition for treating rhinitis as well as preparation method thereof and method for preparing collunarium | |
| CN100457167C (en) | Externally used traditional Chinese medicine preparation for treating nasal mucosa erosion and nosebleed and its preparation method | |
| CN104739946A (en) | Health preserving microcapsule for preventing and treating hyperlipidemia, high blood pressure and high blood sugar | |
| CN107951930A (en) | It is a kind of to be used to treat spray of allergic rhinitis and preparation method thereof | |
| CN102973747A (en) | Bath fumigating liquid and preparation process thereof | |
| CN102813767B (en) | First-aid drug for treating heatstroke and preparation method thereof | |
| CN104984069A (en) | Traditional Chinese medicinal narcotic applied in painless abortion surgery, and preparation method thereof | |
| CN101647841A (en) | New application of herba elephantopi and extractive | |
| CN109106842B (en) | A medicine for stopping smoking and its preparation method | |
| CN105535065A (en) | Medicine composition for treating schizophrenia | |
| CN101884660A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN103585276A (en) | Drug recipe for treating various allergic diseases | |
| CN105395791A (en) | Traditional Chinese medicine for painless induced abortion surgery anesthesia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 510240, No. 40, light Han street, Haizhuqu District, Guangdong, Guangzhou Patentee after: Guangdong Pharmaceutical University Address before: 510006 Guangzhou City, Guangdong Province, Guangzhou University, North Road, No. 280 Patentee before: Guangdong Pharmaceutical University |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171113 Address after: 518035 Guangdong province Shenzhen City Guangming Street high road EVOC Technology Industrial Park, building 1209 unit development Patentee after: SHENZHEN NOURISH ORIGIN BIOTECHNOLOGY CO.,LTD. Address before: 510240, No. 40, light Han street, Haizhuqu District, Guangdong, Guangzhou Patentee before: Guangdong Pharmaceutical University |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20191224 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |